Oculis: Funding, Investors & Team (Oct 2026)
The Oculis platform for drug delivery is a new method that aids the absorption of drugs to both the front and back parts of the eye. This means that it is possible to cure ailments of the rear of the eye with a basic topical treatment. The advantages of the Oculis platform for drug delivery imply that it is possible to treat eye diseases like DME (diabetic macular edema) non-invasively by only applying the medication to the eye. Additionally, the new method has been shown to lessen the number of topical applications necessary to heal eye diseases that are found in the front part of eye in contrast to traditional eye drops.
Oculis has raised $188M across 3 funding rounds on record, the most recent an undisclosed round of $40.3M announced in Jun 2023.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Oculis Company Profile and Key Stats
Latest funding round on record: Jun 2023.
Oculis Funding Rounds
Oculis raised $57.0M in an undisclosed round announced in May 2021.
1.8 years later, an undisclosed round of $91.0M was announced in Mar 2023.
3 months later, an undisclosed round of $40.3M was announced in Jun 2023.
Oculis Founders and Leadership Team
Contact details for the Oculis team: 1 of 3 have an email address on file.
Start 14-day free trial →Oculis Funding Compared to Other Biotechnology Startups
Oculis' latest round of $40.3M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Oculis in Biotechnology and Reykjavík
Companies Similar to Oculis
Genis is a biotechnology company headquartered in Siglufjörður, Iceland. We strive to discover, develop and…
Alvotech is a global biopharmaceutical company, focused on developing biosimilar versions of leading…
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy…
BioLinker is a creation of manufactured science, protein blend packs, and protein.
WhiteLab Genomics develops digital tools that help gene and cell therapy companies develop cheaper drugs…
Tydra Labs is a biotechnology company that transforms crustacean shell waste into chitin and bio-products.
Oculis Funding FAQs
What does Oculis do?
The Oculis platform for drug delivery is a new method that aids the absorption of drugs to both the front and back parts of the eye. This means that it is possible to cure ailments of the rear of the eye with a basic topical treatment. The advantages of the Oculis platform for drug delivery imply that it is possible to treat eye diseases like DME (diabetic macular edema) non-invasively by only applying the medication to the eye. Additionally, the new method has been shown to lessen the number of topical applications necessary to heal eye diseases that are found in the front part of eye in contrast to traditional eye drops.
How much funding has Oculis raised?
Oculis has raised $188M across 3 rounds on record. The most recent is an undisclosed round of $40.3M announced in Jun 2023.
When did Oculis last raise funding?
Oculis' most recent funding round on record is an undisclosed round of $40.3M, announced in Jun 2023.
Who founded Oculis?
FundedIQ lists Einar Stefansson (Founder), Kate Allman (Founder) at Oculis.
Who is the CEO of Oculis?
Riad Sherif is listed as CEO at Oculis.
Where is Oculis headquartered?
Oculis is based in Reykjavík, Gullbringusysla, Iceland.
How many employees does Oculis have?
Oculis is in the 11-50 employee band.
How does Oculis' funding compare to other Biotechnology startups?
Oculis' latest round of $40.3M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Oculis Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Oculis is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.